Cannabis and benzodiazepines are sometimes used by the same people for overlapping reasons: anxiety, panic, insomnia, muscle tension, or simply to reduce mental and physical arousal. Xanax (alprazolam), Ativan (lorazepam), and Klonopin (clonazepam) are all benzodiazepines, but they differ in how quickly they act, how long they remain active, and how the body metabolizes them. Marijuana is equally variable. THC-rich flower, CBD-dominant products, edibles, concentrates, and pharmaceutical cannabidiol do not have identical effects or interaction potential. This makes the question “Can I mix weed and Xanax?” more complicated than a simple yes-or-no answer.
The main concern is that benzodiazepines are central nervous system depressants, while cannabis—particularly THC—can also cause sedation, dizziness, slowed reaction time, impaired coordination, and altered judgment. Combining two substances that can impair alertness may produce more drowsiness or psychomotor impairment than either would alone. A review of cannabinoid-drug interactions notes that cannabis produces sedation and psychomotor impairment and that combining cannabinoids with other sedating drugs can potentiate central nervous system effects.
Direct clinical research specifically examining marijuana with alprazolam, lorazepam, or clonazepam remains surprisingly limited. That absence of evidence is important: many interaction warnings are based on pharmacology, known benzodiazepine effects, cannabinoid metabolism, and studies involving related benzodiazepines rather than large controlled trials of each exact combination.
How Benzodiazepines and Cannabis Affect the Brain Differently
Benzodiazepines work primarily by enhancing the activity of gamma-aminobutyric acid, or GABA, at GABA-A receptors. GABA is the brain’s major inhibitory neurotransmitter. By making GABA signaling more effective, benzodiazepines decrease neuronal excitability, which explains their ability to reduce anxiety, stop certain seizures, relax muscles, and produce sedation. The same mechanism can impair memory, coordination, reaction time, and alertness.
THC works through a very different system. It activates cannabinoid receptors—especially CB1 receptors—distributed widely throughout the brain. These receptors influence memory, perception, motor coordination, reward, appetite, anxiety, and the release of several neurotransmitters, including GABA and glutamate. THC can therefore feel relaxing at one dose but produce confusion, dizziness, panic, rapid heart rate, or impaired concentration at another.
Because the two drugs do not act through exactly the same receptor, combining them does not simply “double” a single biological mechanism. Their functional effects can nevertheless overlap. Both may reduce psychomotor performance, interfere with memory, and alter alertness, so impairment can accumulate even when the drugs reach the brain through different pharmacological pathways.
What Human Research Shows About THC and Benzodiazepines
One of the most informative controlled studies examined oral THC and diazepam, the benzodiazepine sold as Valium. Ten regular cannabis users received THC doses of 5, 15, or 30 milligrams, diazepam doses of 5 or 10 milligrams, and several combinations. Diazepam alone increased ratings of sedation and impaired performance on psychomotor tasks. THC also impaired some measures of performance. When the drugs were combined, the researchers observed additional concerns involving sedation and impairment and recommended caution when cannabinoids and benzodiazepines are used together.
The combination did not produce a dramatically new form of intoxication. Diazepam did not substantially change the characteristic subjective THC response, and the researchers concluded that GABA-A signaling appeared to play only a limited role in THC’s distinctive subjective effects. However, diazepam plus THC increased heart rate above THC alone, and psychomotor impairment remained an important concern.
Another randomized crossover study compared 20 milligrams of oral THC-containing cannabis extract with 5 milligrams of diazepam in healthy women. Cannabis produced significantly greater fatigue, dizziness, drowsiness, and feelings of intoxication than diazepam under those study conditions. Although the drugs were not taken together in that experiment, it demonstrates that oral THC itself can produce many of the same functional side effects that already accompany benzodiazepine treatment.
Cannabis and Xanax (Alprazolam)
Xanax is one of the benzodiazepines for which a metabolic cannabis interaction is especially plausible. Alprazolam is metabolized primarily through the cytochrome P450 CYP3A pathway. Its prescribing information warns that CYP3A inhibitors can slow alprazolam clearance, increase blood concentrations, and raise the risk of adverse effects. Xanax labeling also states that benzodiazepines produce additive CNS-depressant effects when taken with other CNS depressants.
Cannabinoids complicate this because laboratory and clinical interaction research shows that CBD and THC can affect several cytochrome P450 enzymes. A 2024 systematic review found that major cannabinoids are metabolized through CYP3A4, CYP2C9, and CYP2C19 pathways and may interact with medications using the same enzymes. A 2025 review likewise found that CBD consistently inhibited several hepatic enzymes, including CYP3A4 in experimental studies.
That does not prove that ordinary cannabis use raises alprazolam concentrations by a predictable percentage. There is no strong human clinical trial showing that smoking a particular amount of marijuana increases Xanax levels by a specific amount. The metabolism concern is more significant with substantial oral CBD exposure than with assumptions based simply on smoking one cannabis strain. Nevertheless, someone regularly using high-dose CBD products while taking alprazolam has a stronger reason to discuss the combination with a pharmacist or prescriber.
From a practical standpoint, the immediate interaction is more likely to be noticeable as sleepiness, dizziness, poor coordination, memory problems, or stronger-than-expected impairment. Xanax itself carries a warning against driving or operating machinery because of its CNS-depressant effects. Adding THC can make judging one’s own impairment even less reliable.
Cannabis and Ativan (Lorazepam)
Ativan differs from Xanax because lorazepam is not heavily dependent on CYP3A metabolism. Lorazepam is mainly metabolized by glucuronidation, which reduces some of the concern about the CYP3A-mediated interaction that applies to alprazolam. The Ativan label notes, for example, that valproate and probenecid can reduce lorazepam clearance through effects involving glucuronidation.
This does not make marijuana plus Ativan harmless. The more important interaction is pharmacodynamic: both substances can cause drowsiness, impaired coordination, slower responses, and altered cognition. Ativan’s official prescribing information warns that lorazepam produces increased CNS-depressant effects when combined with other CNS depressants. THC does not need to alter lorazepam’s blood concentration to make a person more functionally impaired.
CBD may still present a theoretical metabolic issue because laboratory studies show that CBD can inhibit UGT enzymes, including UGT2B7, which participate in glucuronidation of various medications. Evidence establishing a clinically important CBD-lorazepam interaction in humans is sparse, however. A review of cannabis-medication pharmacokinetics specifically notes that clinical evidence involving cannabinoid effects on UGT pathways remains limited. Therefore, it would be misleading to say cannabis definitively raises Ativan levels; the better-supported warning involves combined sedation and impairment.
Cannabis and Klonopin (Clonazepam)
Klonopin is used for panic disorder as well as certain seizure disorders and generally remains active longer than short-acting benzodiazepines such as alprazolam. Clonazepam metabolism involves the cytochrome P450 3A family, and its prescribing information states that CYP3A inhibitors may impair its metabolism and potentially produce exaggerated concentrations and effects.
That gives CBD products a plausible pharmacokinetic interaction route similar in principle to alprazolam, although again there is no good clinical study demonstrating exactly how much typical cannabis consumption changes clonazepam concentrations. The label also notes that the CNS-depressant effects of benzodiazepines may be potentiated by other sedating substances.
Because clonazepam can remain active for an extended period, timing the two substances several hours apart does not necessarily eliminate overlap. A person taking Klonopin earlier in the day may still have pharmacologically active clonazepam present when using cannabis later that evening. That does not mean a severe interaction will occur every time, but it helps explain why unexpectedly heavy sedation can occur even when the two were not taken simultaneously.
CBD May Matter as Much as THC
Cannabis-drug interaction discussions often focus almost entirely on THC because THC produces intoxication. For benzodiazepines, however, CBD may be especially relevant to drug metabolism. CBD can influence CYP2C19, CYP3A4, and several other metabolic enzymes, particularly at higher oral doses. Reviews consistently caution that CBD-containing products have the potential to change concentrations of medications metabolized through those pathways.
The clearest real-world demonstration involves clobazam, another benzodiazepine used primarily in epilepsy. In one clinical study of children receiving both clobazam and pharmaceutical CBD, concentrations of clobazam’s active metabolite increased dramatically. The average increase in N-desmethylclobazam was about fivefold at four weeks, and many participants required reductions in their clobazam dose because of side effects. A later controlled trial confirmed a significant interaction, with CBD increasing exposure to the active clobazam metabolite approximately 2.6-fold.
Clobazam is not Xanax, Ativan, or Klonopin, so those numbers should not be transferred to other benzodiazepines. The studies are valuable because they prove that clinically significant cannabinoid-benzodiazepine metabolic interactions can occur under some circumstances. They also illustrate why concentrated oral CBD should not automatically be regarded as interaction-free simply because it does not cause a traditional marijuana high.
Sedation, Memory and Coordination Are the Main Immediate Concerns
The most likely noticeable result of combining marijuana with a benzodiazepine is excessive CNS impairment. A person may feel unusually sleepy, dizzy, mentally foggy, unsteady, or forgetful. Reaction time and coordination may deteriorate even if the person does not feel profoundly intoxicated. Experimental driving research independently identifies both cannabis and benzodiazepines as classes capable of impairing psychomotor function.
Memory deserves particular attention. Benzodiazepines can interfere with forming new memories, especially at higher doses, while THC can impair short-term memory and attention. Someone combining the two may consequently have difficulty remembering conversations, decisions, medication doses, or events that occurred while intoxicated. This becomes particularly problematic if the person responds by taking another benzodiazepine because they cannot remember taking the first one.
Falls and injuries are another concern, particularly among older adults or people already prone to dizziness. Cannabis can sometimes cause orthostatic hypotension, while benzodiazepines impair balance and coordination. The combination can therefore make getting up quickly, using stairs, driving, or operating equipment more hazardous.
Does Mixing Cannabis and Benzodiazepines Cause Respiratory Depression?
Benzodiazepines are particularly dangerous when combined with opioids, alcohol, or other strong CNS depressants. The FDA requires a boxed warning across the benzodiazepine class because combinations—especially with opioids—can cause profound sedation, respiratory depression, coma, and death.
Cannabis is different from opioids in this respect. THC does not typically produce the same profound respiratory suppression seen with opioid overdose, and available evidence does not establish that cannabis plus a therapeutic benzodiazepine commonly causes life-threatening respiratory depression by itself. Claims that marijuana and Xanax routinely “stop breathing” would therefore overstate the evidence.
The situation changes substantially when alcohol, opioids, sleep medications, sedating antihistamines, or additional benzodiazepines are added. Polysubstance exposure removes much of the reassurance provided by cannabis’s comparatively modest effect on respiration. Anyone experiencing markedly slowed or shallow breathing, inability to stay awake, blue or gray lips, loss of consciousness, or inability to be awakened needs emergency medical attention.
Cannabis Can Sometimes Increase Anxiety Instead of Treating It
One reason marijuana and benzodiazepines are commonly combined is anxiety. Someone may use cannabis to relax and then take Xanax, Ativan, or Klonopin if the THC produces panic. Clinically, this is understandable: acute cannabis intoxication can provoke substantial anxiety, palpitations, paranoia, or panic in susceptible people.
Using an already-prescribed benzodiazepine to treat cannabis-induced anxiety should nevertheless not become an automatic strategy without discussing the pattern with the prescriber. Repeatedly using strong THC followed by a benzodiazepine creates a cycle in which one psychoactive substance is being used to counteract the adverse effects of another. It can also make it more difficult to recognize escalating benzodiazepine use, tolerance, or dependence.
If cannabis repeatedly triggers panic severe enough to require rescue medication, reducing or avoiding the THC exposure is generally a more direct risk-reduction approach than continually adding another sedating drug.
Benzodiazepine Dependence and Withdrawal Are a Separate Risk
Cannabis should not be used as justification to abruptly stop a benzodiazepine. The FDA warns that physical dependence can develop even when benzodiazepines are taken exactly as prescribed, sometimes after days to weeks of regular use. Rapid reduction or sudden discontinuation can produce serious withdrawal reactions, including seizures.
Some people report using marijuana or CBD while tapering benzodiazepines because they hope cannabis will control anxiety or insomnia. Research has not established cannabis as a reliable treatment for benzodiazepine withdrawal, and feeling temporarily calmer does not protect against potentially dangerous physiological withdrawal.
Anyone who has taken Xanax, Ativan, Klonopin, or another benzodiazepine regularly should therefore discuss discontinuation with the prescriber and use an individualized taper rather than stopping suddenly. Cannabis may alter how withdrawal symptoms feel, but it does not remove the underlying dependence risk.
Practical Safety Considerations
People using prescribed benzodiazepines should make sure their physician or pharmacist knows about THC, CBD, medical marijuana, hemp extracts, and other cannabinoid products, particularly when cannabis use is frequent or CBD doses are substantial. This gives the clinician a chance to review metabolism, other medications, liver function, and symptoms such as excessive sedation rather than evaluating the benzodiazepine in isolation.
Driving and other activities requiring coordination should be avoided when the combination causes impairment. Alcohol and opioids deserve particular caution because adding them can transform a comparatively manageable cannabis-benzodiazepine interaction into a much more dangerous polysubstance exposure. Benzodiazepine doses should not be increased or reduced simply to compensate for marijuana effects without guidance from the prescriber.
Symptoms such as mild sleepiness or dizziness may reflect overlapping drug effects, but extreme sedation, severe confusion, repeated fainting, difficulty breathing, inability to awaken normally, or loss of consciousness require urgent medical evaluation.
Final Thoughts on Marijuana, Xanax, Ativan and Klonopin
Cannabis and benzodiazepines can interact, but the interaction is more nuanced than many warnings suggest. The strongest immediate concern is additive sedation and impairment. Human research combining THC with diazepam found psychomotor impairment and increased sedation, supporting caution when cannabinoids and benzodiazepines are used together.
Metabolic interactions differ among individual benzodiazepines. Xanax and Klonopin involve CYP3A metabolism, making interactions with cannabinoid products—particularly concentrated CBD—biologically plausible. Ativan relies primarily on glucuronidation, so CYP3A interactions are less central, although combined CNS depression remains relevant. Evidence from clobazam provides proof that CBD can meaningfully alter the disposition of at least some benzodiazepines, but researchers cannot assume the same magnitude of interaction for alprazolam, lorazepam, or clonazepam.
For someone prescribed a benzodiazepine, the most important issues are not simply whether cannabis is “safe” or “unsafe.” THC dose, CBD dose, benzodiazepine type, other medications, alcohol or opioid use, frequency of cannabis use, and individual sensitivity all affect the risk. The available evidence supports caution, particularly with high doses and multiple sedating substances, while also making clear that more direct clinical research on cannabis with Xanax, Ativan, and Klonopin is still needed.
